Although the world now has a number of vaccines in place and available to serve as a preventative and/or impact-reduction method for COVID, there are a number of reasons that it is also important for the Pharma and Biopharma industries to continue developing other treatment and medicines to for those who become infected – with or without having taken the vaccine. Lucky for all of us, there are a few small molecule agents coming available for COVID patients in 2022, and during episode 51 of “The Weekly Bioanalysis”, John and Dom discuss all the small molecule drugs being developed to meet these needs.


To view/listen to the episode of “the Weekly Bioanalysis” click the play button below!


You can always find the latest episode of “The Weekly Bioanalysis” here,

but you can also subscribe to the podcast on Apple Podcasts or any of the major podcast distribution channels!


We would love to hear from you about questions you have from our podcast – or even feedback on how we could improve it!

Please use the form below to reach out to us.

Scroll to Top